price
NASDAQ · REGN
Regeneron Pharmaceuticals, Inc.
Healthcare · Biotechnology
$774.11
Down-$19.63 (-2.47%)
Updated Sep 16, 2026, 10:03 AM
SID Score
6.9/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 77.16B
- P/E ratio
- 16.91
- Dividend yield
- 0.45%
- 52-week range
- $591.52 – $859.34
- Volume
- 540.84K
- Avg. volume
- 1.09M
Price performance
REGN price history
1M range · 20 trading sessions · Daily adjusted prices
REGN closed at $774.11 after 20 trading sessions, down 4.46% for the selected period.
- Last close
- $774.11
- Period change
- -4.46%
- Period low
- $774.11
- Period high
- $852.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $788.53 | $788.58 | $769.5725 | $774.11 | 540.84K |
| Sep 14, 2026 | $791.98 | $798.8352 | $779.45 | $793.74 | 591.3K |
| Sep 11, 2026 | $800.00 | $800.22 | $780.81 | $781.49 | 443.99K |
| Sep 10, 2026 | $794.36 | $806.14 | $792.00 | $793.26 | 526.91K |
| Sep 9, 2026 | $803.83 | $808.63 | $796.725 | $807.65 | 621.46K |
| Sep 8, 2026 | $814.36 | $821.17 | $799.42 | $810.31 | 556.54K |
| Sep 4, 2026 | $840.055 | $841.54 | $825.83 | $827.72 | 561.17K |
| Sep 3, 2026 | $858.185 | $859.34 | $837.63 | $843.47 | 496.26K |
| Sep 2, 2026 | $826.24 | $854.4865 | $825.77 | $852.03 | 749.45K |
| Sep 1, 2026 | $808.86 | $824.63 | $804.32 | $823.82 | 682.81K |
| Aug 31, 2026 | $782.44 | $802.78 | $779.08 | $799.08 | 894.27K |
| Aug 28, 2026 | $809.40 | $809.40 | $789.075 | $794.19 | 488.31K |
| Aug 27, 2026 | $806.18 | $817.62 | $804.27 | $807.71 | 766.99K |
| Aug 26, 2026 | $827.78 | $831.67 | $814.70 | $814.79 | 585.37K |
| Aug 25, 2026 | $829.22 | $839.94 | $823.44 | $833.56 | 505.42K |
| Aug 24, 2026 | $834.51 | $834.695 | $823.395 | $828.50 | 672.01K |
| Aug 21, 2026 | $835.74 | $847.00 | $826.64 | $834.04 | 786.92K |
| Aug 20, 2026 | $831.70 | $840.8199 | $826.05 | $826.64 | 596.47K |
| Aug 19, 2026 | $817.17 | $844.92 | $815.38 | $840.84 | 750.45K |
| Aug 18, 2026 | $814.00 | $821.02 | $805.93 | $810.24 | 779.07K |
Latest REGN news
The latest Smart Investors Daily articles mentioning REGN.
Stock researchCompany · Overview
REGN research
Overview
Company profile and research snapshot.
Company profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $776.80
- Implied upside
- —
- Analysts
- 22
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Buy | — |
| Aug 17, 2026 | Leerink Partners | Market Perform | — |
| Aug 3, 2026 | Guggenheim | Buy | — |
| Aug 3, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.